News
Long-term Benefit of Luspatercept Therapy – Fresh Data from the MEDALIST Study
The goal of therapy for low-risk myelodysplastic syndrome (MDS) is to compensate for anemia, improve or maintain quality of life, and prolong the time to progression to higher-risk MDS (HR-MDS) or acute myeloid leukemia (AML). To manage anemia, we can resort to transfusion therapy or administer epoetins, lenalidomide, or luspatercept, the first representative of a class of drugs that support erythrocyte maturation. Last year's data from the follow-up of patients enrolled in the MEDALIST study pertain specifically to the latter.
Use of Medical Cannabis in Patients with Fibromyalgia to Relieve Pain and Depression
Medical cannabis is prescribed to patients with chronic pain resistant to conventional treatments.…
Pilot Program for Lung Cancer Screening in the Czech Republic – Current Interim Results
Since January 1, 2022, a pilot population program for lung cancer screening has been underway in…
Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?
The journal Vnitřní lékařství recently published the results of a survey conducted among outpatient…
Artificial Intelligence Helps in Selecting Influenza Strains for Vaccine Production
Vaccination is one of the most important and effective preventive measures in the fight against…
Central European Expert Consensus on the Treatment of ITP in Adult Patients
In a recently published consensus, experts from Central Europe evaluate the current treatment…
How do patients perceive the treatment of ITP with romiplostim?
Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin…
FDA Warns Against Self-Monitoring Glucose Using Smartwatches. What About in Czechia?
On February 21st, the U.S. Food and Drug Administration (FDA) issued a warning aimed at diabetic…
Where radical surgery cannot be performed in the subhepatic region or liver, there is room for radiation treatment
Proton radiotherapy continues to expand its indications in the treatment of oncological diseases.…
You wouldn't believe what our AI can already do! "Snapshots" from research – 2024/8
Will we soon be living among robots? Artificial Intelligence (AI) has learned to design antibodies,…